Skip to main content
Caplight Logo









PDX Pharmaceuticals

PDX Pharmaceuticals

Private
Portland, OregonHealthcare & Life Scienceshttps://www.pdxpharm.com/

Last Round

Grant

Sep 23, 2024

Total Funding Raised

$8.22M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

PDX Pharmaceuticals is a biopharmaceutical company that develops next-generation combination immunotherapies for cancer using a novel nanotechnology platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Advanced Materials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

nano-immunotherapynanoparticle drug deliverynanotherapeuticssiRNA deliverynanomedicinetherapeutic co-deliverysolid tumor therapydrug resistance in cancerimmuno-oncologygene silencing therapyprecision medicinesilica nanoparticlesIND-enabling studiesbiotech licensingSBIRSmall Business Innovation Research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PDX Pharmaceuticals Comparables

Compare PDX Pharmaceuticals with similar companies based on industry and business-model similarity.

PDX Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Lemonex Inc.
79%
Thalia Therapeutics PLC
76%
Sirnaomics
74%

PDX Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 23, 2024
GrantJul 6, 2023
GrantFeb 21, 2023
Series A ExtensionFeb 9, 2021
Series AJan 16, 2020
Grant
May 1, 2017

Key People

Founding team and executive leadership

Wassana Yantasee

President CEO

Executive Team

Worapol Ngamcherdtrakul

Head Of Research & COO

Executive Team

PDX Pharmaceuticals Investors

Notable investors and investment history

PDX Pharmaceuticals investors
InvestorRounds
National Cancer InstituteGrant
The Wayne D. Kuni & Joan E. Kuni FoundationSeries A, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 27, 5.8x the trailing average.

  • Jan 20, 2026

    Monthly visitors increased 289% MoM, reaching 3.5K.

PDX Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

PDX Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about PDX Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersPortland, Oregon
Employee Range8
Year Founded2010
Last FundingSep 23, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?